oxalates has been researched along with Ascorbic-Acid-Deficiency* in 5 studies
5 other study(ies) available for oxalates and Ascorbic-Acid-Deficiency
Article | Year |
---|---|
Vitamin C deficiency and impact of vitamin C administration among pediatric patients with advanced chronic kidney disease.
Vitamin C deficiency is common in chronic kidney disease (CKD) due to losses through dialysis and dietary intake below requirement. We investigated prevalence of vitamin C deficiency and impact of vitamin C treatment in deficient/insufficient patients.. A prospective cohort study in patients aged 1-18 years with CKD stages 4 and 5D collected demographic data including underlying disease, treatment, and anthropometric assessment. Vitamin C intake was assessed using 24-h dietary recall. Hemoglobin, iron status, serum vitamin C, and serum oxalate were measured at baseline and after treatment. Vitamin C (250 mg/day) was given orally for 3 months to deficient/insufficient patients.. Nineteen patients (mean age 12.00 ± 4.1 years) showed prevalence of 10.6% vitamin C insufficiency and 78.9% deficiency. There were no associations between vitamin C level and daily vitamin C intake (p = 0.64) or nutritional status (p = 0.87). Median serum vitamin C was 1.51 (0.30-1.90) mg/L. In 16 patients receiving treatment, median serum vitamin C increased from 1.30 (0.23-1.78) to 3.22 (1.77-5.96) mg/L (p = 0.008) without increasing serum oxalate (79.92 (56.6-106.84) vs. 80.47 (56.88-102.95) μmol/L, p = 0.82). However, 62.5% failed to achieve normal vitamin C levels. Ordinal regression analysis revealed patients with non-oligoanuric CKD were less likely to achieve normal vitamin C levels (β = - 3.41, p = 0.03).. We describe high prevalence of vitamin C insufficiency/deficiency among pediatric CKD patients. Vitamin C levels could not be solely predicted by nutritional status or daily intake. The treatment regimen raised serum vitamin C without increasing serum oxalate; however, it was largely insufficient to normalize levels, particularly in non-oligoanuric CKD. Graphical abstract . Topics: Adolescent; Ascorbic Acid; Ascorbic Acid Deficiency; Child; Humans; Oxalates; Prevalence; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D; Vitamin D Deficiency; Vitamins | 2021 |
Vitamin C neglect in hemodialysis: sailing between Scylla and Charybdis.
In our efforts to meet the vitamin C requirements of dialysis patients we confront a medical dilemma--do we allow the patient to become depleted of vitamin C, with the accompanying hematological and other consequences (Scylla), or do we provide for adequate tissue levels of vitamin C, which has been thought to carry the risk of oxalosis (Charybdis). Many practitioners are certain that either one outcome (deficiency) or the other (oxalic acid toxicity) is inevitable, and much like Odysseus, no safe course is to be found. The recent accumulating evidence that vitamin C improves the management of anemia in dialysis patients compels us to find a safe passage through this dilemma. The serious vitamin C deficiency seen in many patients may also contribute to poor oral health and chronic fatigue. The evidence for oxalosis from vitamin C supplements stems from hemodialysis as practiced 20 years ago. Investigators using this therapy are not observing systemic oxalosis, and the most current data support the conclusion that vitamin C therapy is safe for dialysis patients. The question will be resolved by controlled trials that address both vitamin C effectiveness and safety. Topics: Antioxidants; Ascorbic Acid; Ascorbic Acid Deficiency; Erythropoiesis; Fatigue; Humans; Hyperoxaluria; Oral Health; Oxalates; Renal Dialysis | 2007 |
Correction of subclinical ascorbate deficiency in patients receiving dialysis: effects on plasma oxalate, serum cholesterol, and capillary fragility.
Whole blood ascorbate, plasma oxalate, serum cholesterol, and capillary fragility were measured at monthly intervals for 3 mth in 7 patients receiving continuous ambulatory peritoneal dialysis and 4 receiving haemodialysis, to whom ascorbate supplements had not been prescribed for at least 12 mth. Ascorbate supplements, 25 mg/day, were prescribed for the first month and 50 mg/day for the second month; in the final month patients received no supplements. Whole blood ascorbate was below normal in 6/11 patients at the start of the study but was normal in 10/11 patients when taking ascorbate 50 mg/day. No significant changes in plasma oxalate were observed with these doses of ascorbate, and correction of ascorbate deficiency had no effect on serum cholesterol, mean cell volume, or the results of capillary fragility tests. In a supplementary study, ascorbic acid 500 mg/day was administered for 3 wk to 11 patients. This resulted in a significant rise in mean plasma oxalate from 30.3 (SEM 3.5) to 48.4 (SEM 20.3) mumol/l. Topics: Ascorbic Acid; Ascorbic Acid Deficiency; Bilirubin; Capillary Fragility; Cholesterol; Creatinine; Female; Hemoglobins; Humans; Male; Middle Aged; Oxalates; Renal Dialysis; Triglycerides | 1989 |
Ascorbic acid aggravates secondary hyperoxalemia in patients on chronic hemodialysis.
Topics: Adult; Ascorbic Acid; Ascorbic Acid Deficiency; Female; Humans; Kidney Failure, Chronic; Male; Oxalates; Oxalic Acid; Renal Dialysis | 1984 |
Iron, ascorbic acid, and thalassemia.
Topics: Animals; Ascorbic Acid; Ascorbic Acid Deficiency; Black People; Child; Disease Models, Animal; Guinea Pigs; Hemosiderosis; Humans; Iron; Leukocytes; Liver; Oxalates; South Africa; Thalassemia | 1976 |